Scleromyositis
WikiDoc Resources for Scleromyositis |
Articles |
---|
Most recent articles on Scleromyositis Most cited articles on Scleromyositis |
Media |
Powerpoint slides on Scleromyositis |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Scleromyositis at Clinical Trials.gov Trial results on Scleromyositis Clinical Trials on Scleromyositis at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Scleromyositis NICE Guidance on Scleromyositis
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Scleromyositis Discussion groups on Scleromyositis Patient Handouts on Scleromyositis Directions to Hospitals Treating Scleromyositis Risk calculators and risk factors for Scleromyositis
|
Healthcare Provider Resources |
Causes & Risk Factors for Scleromyositis |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: PM/Scl overlap syndrome
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Scleromyositis or the PM/Scl overlap syndrome is an autoimmune disease in which the immune system attacks the body. Patients with scleromyositis have symptoms of both systemic scleroderma and either polymyositis or dermatomyositis, and is therefore considered an overlap syndrome. Although it is a rare disease, it is one of the more common overlap syndromes seen in scleroderma patients, together with MCTD and synthetase syndrome. Autoantibodies often found in these patients are the anti-PM/Scl (anti-exosome) antibodies.[1]
The symptoms that are seen most often are typical symptoms of the individual autoimmune diseases and include Raynaud's phenomenon, arthritis, myositis and scleroderma.[2] Treatment of these patients is therefore strongly dependant on the exact symptoms with which a patient reports to a physician and is similar to treatment for the individual autoimmune disease, often involving either immunosuppressive or immunomodulating drugs.[3]
References
- ↑ S Jablonska , M Blaszczyk (1999). "Scleroderma overlap syndromes". Adv Exp Med Biol. 455: 85–92. PMID 10599327.
- ↑ Mahler; et al. (2007). "Novel aspects of autoantibodies to the PM/Scl complex: Clinical, genetic and diagnostic insights". Autoimmunity Reviews. 6: 432–7. PMID 17643929.
- ↑ Jablonska; et al. (1998). "Scleromyositis: a scleroderma/polymyositis overlap syndrome". Clinical Rheumatology. 17: 465–7. PMID 9890673.